Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3047% above fair value
$2.38−0.13 (-4.99%)
Close on Nov 11, 2026Market cap $365.52MP/E –Yield –
Editas Medicine statistics
82 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 11, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 4.32
- 2.39
Enterprise valuationIndustry
- EV / Sales
- 4.66
- 2.65
Share statisticsIndustry
- Shares Change (YoY)
- 37.6%
- 10.9%
- Shares Change (QoQ)
- 0.00%
- 0.51%
- Float
- 153M
- 49M
- Shares Held by Insiders
- 0.45%
- 11.6%
- Shares Held by Institutions
- 78.3%
- 56.4%
Short sellingIndustry
- Short Interest
- 39M
- –
- Short Interest Change
- 1.40%
- -0.76%
- Short % of Float
- 25.3%
- 9.06%
- Short % of Shares Outstanding
- 25.2%
- 6.38%
- Days to Cover
- 17.60
- 5.16
Stock price statisticsIndustry
- 52-Week High
- $3.94
- –
- 52-Week Low
- $1.66
- –
- 20-Day Moving Average
- $2.57
- –
- 50-Day Moving Average
- $2.67
- –
- 200-Day Moving Average
- $2.70
- –
- Average True Range (14)
- $0.23
- –
- Price Change (1 Week)
- -12.5%
- -0.50%
- Price Change (1 Month)
- -2.66%
- -0.33%
- Price Change (3 Months)
- -15.3%
- -17.2%
- Price Change (6 Months)
- -17.9%
- -20.1%
- Price Change (YTD)
- 16.1%
- -20.1%
- Price Change (1 Year)
- -5.56%
- -19.3%
- Price Change (3 Years)
- -69.0%
- -23.4%
- Price Change (5 Years)
- -93.7%
- -76.4%
- Price Change (10 Years)
- -85.4%
- -62.4%
- Average Volume (10 Days)
- 2M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 0.81
- 0.73
- Relative Strength Index (14)
- 43.0
- 47.6
- Volatility (1 Year)
- 82.6%
- 80.2%
- Beta (5 Years)
- 2.19
- 1.07
MarginsIndustry
- EBITDA Margin
- -151.7%
- -25.0%
- FCF Margin
- -221.7%
- -9.55%
Returns on capitalIndustry
- Return on Equity (ROE)
- -147.4%
- -51.3%
- Return on Assets (ROA)
- -34.3%
- -40.3%
- Return on Capital Employed (ROCE)
- -51.1%
- -37.7%
Financial positionIndustry
- Current Ratio
- 2.82
- 3.30
- Quick Ratio
- 2.77
- 2.37
- Debt / Equity
- 0.67
- 0.49
- Interest Coverage
- -10.58
- -6.27
GrowthIndustry
- Revenue Growth (YoY)
- 7.43%
- 7.01%
- Revenue Growth (3Y CAGR)
- 27.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- -14.9%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.24
- 0.40
- Revenue Per Employee
- $572.72K
- $426.63K
- Profits Per Employee
- -$830.17K
- -$680.86K
- Employee Count
- 87
- 75
- WACC
- 15.0%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $133.38M
- $16.31M
- Net Cash Per Share
- $0.87
- $0.70
- Equity (Book Value)
- $84.52M
- $53.12M
- Book Value Per Share
- $0.55
- $1.49
- Tangible Book Value
- $84.52M
- $26.11M
- Working Capital
- $130.39M
- $77.59M
Cash flow (TTM)Industry
- Capital Expenditures
- -$258.00K
- -$939.00K
- FCF Per Share
- -$0.72
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -19.8%
- -19.8%
- FCF Yield
- -30.2%
- -8.81%
- Buyback Yield
- -36.6%
- -0.69%
- Shareholder Yield
- -36.6%
- 0.00%
Taxes and interestIndustry
- Interest Expense
- $7.14M
- $2.98M
Scores and fair valueIndustry
- Altman Z-Score
- -9.39
- 0.28
- Piotroski F-Score
- 1
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EDIT | S&P 500 | Difference | EDIT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.9% | -2.4% | −15.5 pts | ||
| 3 months | -19.3% | -1.2% | −18.2 pts | ||
| Year to date | +16.1% | +12.3% | +3.8 pts | ||
| 1 year | -10.5% | +12.4% | −23.0 pts | ||
| 3 years | -69.0% | +78.8% | −147.8 pts | -32.3% | +21.4% |
| 5 years | -93.8% | +75.2% | −168.9 pts | -42.6% | +11.9% |
| 10 years | -85.4% | +311.1% | −396.5 pts | -17.5% | +15.2% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
39M EDIT shares were sold short on Oct 30, 2026, up 1.4% from the previous report, or 25.33% of the shares available to trade. At recent volumes it would take 17.6 days to buy them back. Over the last 20 sessions, 53.0% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 38,720,295 | +1.4% | 2,199,477 | 17.6 |
| Oct 15, 2026 | 38,185,007 | +2.9% | 2,662,723 | 14.3 |
| Sep 30, 2026 | 37,109,260 | +23.8% | 3,970,413 | 9.3 |
| Sep 15, 2026 | 29,964,193 | -0.9% | 1,906,017 | 15.7 |
| Aug 31, 2026 | 30,232,239 | +22.5% | 3,372,729 | 9.0 |
| Aug 14, 2026 | 24,686,466 | +5.2% | 1,692,123 | 14.6 |
| Jul 31, 2026 | 23,464,219 | +5.7% | 1,289,898 | 18.2 |
| Jul 15, 2026 | 22,197,638 | -1.2% | 2,766,681 | 8.0 |
| Jun 30, 2026 | 22,473,029 | +22.0% | 3,116,110 | 7.2 |
| Jun 15, 2026 | 18,414,894 | +22.2% | 2,390,764 | 7.7 |
| May 29, 2026 | 15,066,130 | +57.6% | 4,478,910 | 3.4 |
| May 15, 2026 | 9,561,026 | -4.5% | 1,116,594 | 8.6 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?